Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

e replay, go to www.genvec.com, click on "Investor Relations," and click on "Webcasts and Data."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to certain of our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of thi
'/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... GUELPH, ON , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: ... month period ended March 31, 2015.  Biorem,s complete 2015 first quarter ... ). Financial Summary:Three-months ended March 31,(in CDN$,000 ... Revenue , 4,689 , 1,974 Gross profit , ... , (318) Net earnings (loss) , 528 , ...
(Date:6/1/2015)... Regis Technologies, Inc. is a ... stationary phases (CSPs) for analytical and preparative chromatography ... presenting solutions for new clients, Regis implemented a ... addition to its core expertise in chiral chromatography ... tackle projects for the scale clients need–from milligram ...
(Date:6/1/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today that ... leading commercial food testing laboratory based in southwest ... as a base for the company,s new operations in ... House was incorporated in 1990, and its business has ... water quality testing for major hotels and restaurants in its ...
(Date:6/1/2015)... ROUGE, La. , June 1, 2015 ... Phase II trial of lead candidate EP-100 in ovarian ... membrane-disrupting peptide designed to seek and destroy cancer cells ... surfaces. LHRH receptors are over-expressed in a wide range ... randomized, multi-center Phase II trial of EP-100 were ...
Breaking Biology Technology:Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Neogen acquires India food safety company 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... of the fruit fly and roundworm,s functional genomic elements: DNA ... which genes are turned on and off at various times ... of the Human Genome Project, the genomes of the fruit ... elegans , are powerful models for understanding human biology ...
... (Nasdaq: NEOG ) announces the following Webcast:What: ... January 4, 2011 @ 11:00 ETWhere: , http://www.videonewswire.com/event.asp?id=75037 ... on to the web at the address above.  Contact: ... are unable to participate during the live webcast, the ...
... (December 21, 2010) -- A researcher known widely ... and use of minimally toxic, environmentally friendly chemicals ... Dr. Paul Anastas, science advisor to the ... for the EPA,s Office of Research and Development ...
Cached Biology Technology:Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 2Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 3Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 4Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations 2Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations 3
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... Researchers at Rensselaer Polytechnic Institute have developed a new ... a simple sheet of black paper. The nanoengineered ... toward meeting the trickiest design and energy requirements of ... Along with its ability to function in temperatures up ...
... energy sources, such as wind, solar, and geothermal add ... materials sourcing, manufacture, running, and decommissioning" Researchers in Greece ... the answer. Increasing energy consumption and a growing ... the use of fossil fuels brings with it the ...
... Do bats use their ultrasonic echolocation calls to recognise ... of Biogeography by Danilo Russo and colleagues suggests that ... These bats find their way in the dark and ... made of a constant frequency. Different rhinolophid species show ...
Cached Biology News:Beyond batteries: Storing power in a sheet of paper 2Beyond batteries: Storing power in a sheet of paper 3Adding up renewable energy 2A 'private bandwidth' for communication in bats: Evidence from insular horseshoe bats 2
WTAP Antibody...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: